Clinicopathological characteristics | Overall survival (n = 1144) | Progression-free survival (n = 596) | ||||
---|---|---|---|---|---|---|
N | HR | P value | N | HR | P value | |
Gender | ||||||
 Male | 659 | 0.64 (0.52–0.79) | 2.20E−05 | 343 | 0.61 (0.43–0.86) | 0.0043 |
 Female | 374 | 0.86 (0.61–1.21) | 0.38 | 253 | 0.77 (0.49–1.20) | 0.25 |
Stage | ||||||
 1 | 449 | 1.46 (1.06–2.00) | 0.02 | 596 | 1.26 (0.81–1.95) | 0.31 |
 2 | 161 | 0.99 (0.63–1.55) | 0.95 | 125 | 0.64 (0.38–1.11) | 0.108 |
 3 | 44 | 1.11 (0.55–2.25) | 0.77 | 17 | – | – |
AJCC stage T | ||||||
 1 | 224 | 0.86 (0.57–1.28) | 0.44 | 54 | 0.95 (0.23–3.53) | 0.94 |
 2 | 190 | 0.86 (0.58–1.27) | 0.44 | 121 | 1.75 (0.94–3.27) | 0.073 |
 3 | 29 | 0.83 (0.38–1.85) | 0.65 | 2 | – | – |
 4 | 23 | 0.74 (0.30–1.84) | 0.52 | 0 | – | – |
AJCC stage N | ||||||
 0 | 324 | 0.87 (0.63–1.19) | 0.38 | 126 | 2.18 (1.06–4.46) | 0.029 |
 1 | 102 | 0.64 (0.38–1.08) | 0.09 | 51 | 0.98 (0.40–2.41) | 0.96 |
 2 | 32 | 0.39 (0.17–0.86) | 0.016 | 0 | – | – |
AJCC stage M | ||||||
 0 | 462 | 0.73 (0.56–0.93) | 0.013 | 177 | 1.66 (0.95–2.9) | 0.07 |
Smoking history | ||||||
 Yes | 300 | 1.59 (1.04–2.24) | 0.029 | 297 | 0.73 (0.48–1.08) | 0.11 |
 No | 141 | 2.24 (0.96–5.25) | 0.056 | 141 | 1.39 (0.75–2.58) | 0.29 |
Chemotherapy | ||||||
 Yes | 34 | 0.82 (0.26–2.64) | 0.74 | 34 | 1.18 (0.45–3.11) | 0.74 |
 No | 21 | 0.18 (0.02–1.52) | 0.075 | 21 | 0.63 (0.19–2.07) | 0.44 |